Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950103-24-002384
Filing Date
2024-02-20
Accepted
2024-02-20 11:40:06
Documents
2
Group Members
DONGLIANG LINFEI YANGHE XIE AI QI INVESTMENT MANAGEMENT (BEIJING) CO., LTD.HUGO SHONGJIANGUANG LIJINGBO WANGKUIGUANG NIUSNOW MOON LTDTIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)XIZANG HEXIE INVESTMENT MANAGEMENT CO., LTD.ZHUHAI HEXIE ZHIYUAN MA

Document Format Files

Seq Description Document Type Size
1 FORM SC 13D/A dp206703_sc13da.htm SC 13D/A 245797
2 EXHIBIT 99.4 dp206703_ex9904.htm EX-99.4 26655
  Complete submission text file 0000950103-24-002384.txt   274785
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc (DE) (Subject) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-46247 | Film No.: 24651606
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 957 OFFSHORE INCORPORATIONS CENTRE ROAD TOWN TORTOLA D8 00000
Business Address P.O. BOX 957 OFFSHORE INCORPORATIONS CENTRE ROAD TOWN TORTOLA D8 00000 852 2127 4863
SPARKLE BYTE LTD (Filed by) CIK: 0001663831 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: SC 13D/A